Another study conducted on 89 patients who underwent SBRT for early-stage non-small cell lung cancer (NSCLC) analyzed the levels of T cells and key transcription factors, including RORγt (Th17), TBX21 (Th1), GATA-3 (Th2), and FoxP3 (Treg), in peripheral blood samples taken before, 2 weeks, and 12 weeks after treatment. Here, FOXP3 is linked to non-small cell lung carcinoma.